DeLiver Pharma ApS: Financial statements 2021
CVR: 39432714
Source: annual report 2021, Danish Business Authority
01/01/2021 – 31/12/2021
DeLiver Pharma ApS (CVR 39432714) has filed annual accounts for 2021. In 2021, the company reported a gross profit of DKK -21,884 and a net result of DKK -146,911 compared with DKK -113,852 the year before. Equity in the 2021 report amounted to DKK 138,818. The solvency ratio was 92.8%.
- Gross Profit
- DKK -21,884
- Profit/Loss
- DKK -146,911
- Equity
- DKK 138,818
- Total Assets
- DKK 149,520
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2021 | - | -22K | -147K | 139K | - |
| 2020 | - | -20K | -114K | 246K | - |
| 2019 | 79K | 51K | -12K | 220K | - |
Official annual report
Find more companies like DeLiver Pharma ApS
Build lead lists with filters on industry, geography, size and financials, and export straight to Excel.
Try the lead list generatorEvents in 2021
DeLiver Pharma ApS has published its annual report for 2020. Gross profit came to DKK -19,597, and the net result was DKK -113,852.
About DeLiver Pharma ApS
DeLiver Pharma ApS is a Danish company of the type Anpartsselskab based in Faaborg, founded in 2018. The company is registered under the industry Fremstilling af farmaceutiske præparater. The management consists of Niels Jonas Heilskov Graversen. The board consists of Jens Kristian Damsgaard (chair), Holger Jon Møller, Niels Jonas Heilskov Graversen and Søren Kragh Moestrup. The company's owners include MOESTRUP HOLDING 2007 ApS, MØLLER HOLDING 2007 ApS and PHIDEAS ApS. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of DKK -20,487 and a net result of DKK -31,867 compared with DKK -21,682 the year before. Equity in the 2025 report amounted to DKK 163,221.